Chapter IV. Clinical Trials

Rev Diabet Stud, 2012, 9(4):372-381 DOI 10.1900/RDS.2012.9.372

CD3 Monoclonal Antibodies: A First Step Towards Operational Immune Tolerance in the Clinic

Lucienne Chatenoud1,2, Herman Waldmann3

1INSERM U1013, Necker Hospital, Paris, France
2Universite Paris Descartes, Sorbonne Paris Cite, Paris, France
3University of Oxford, Sir William Dunn School of Pathology, South Parks Road, Oxford OX1 3RE, UK
Address correspondence to: Lucienne Chatenoud, e-mail lucienne.chatenoud@inserm.fr, or Herman Waldmann, e-mail herman.waldmann@path.ox.ac.uk

Manuscript submitted December 19, 2012; resubmitted January 31, 2013; accepted February 9, 2013.

Keywords: type 1 diabetes, immune tolerance, anti-CD3 antibody, OKT3, beta-cell, Fc receptor

Abstract

Type 1 diabetes (T1D) is a prototypic organ-specific autoimmune disease resulting from the selective destruction of insulin-secreting β-cells within the pancreatic islets of Langerhans. It is caused by an immune-mediated inflammation, involving autoreactive CD4+ and CD8+ T lymphocytes that infiltrate the islets and initiate insulitis. The use of exogenous insulin is the current standard treatment. However, in spite of significant advances, this therapy is still associated with major constraints, including risk of hypoglycemia and severe degenerative complications. As T1D mainly affects children and young adults, any candidate immune therapy must be safe, and it must avoid a sustained depression of immune responses with all its attendant problems of recurrent infection and drug toxicity. In this context, inducing or restoring immune tolerance to target autoantigens would be the ideal approach. We refer to immune tolerance here as the selective damping of the damaging autoimmune response following a short treatment, while keeping intact the capacity of the host to respond normally to exogenous antigens. The therapeutic approach we discuss in this article originates from attempts to induce tolerance both to soluble antigens and tissue antigens (i.e. alloantigens and autoantigens) by using biological agents that selectively interfere with lymphocyte activation, namely polyclonal and monoclonal anti-T cell antibodies. The challenged dogma was that, in an adult-primed immune system, it was not possible to restore self-tolerance therapeutically without the use of exogenous autoantigen administration. The reality has been that, in diabetes, endogenous host autoantigen can fulfill this role because a significant amount of functioning β-cells remains, even at the time of established hyperglycemia. Experimental results obtained in the 1990s showed that a short-term CD3 antibody treatment in recently diagnosed diabetic non-obese diabetic (NOD) mice induced permanent remission of the disease by restoring self-tolerance. Based on these findings, phase I, II, and III trials were conducted using two distinct humanized Fc-mutated antibodies to human CD3, namely ChAglyCD3 (otelixizumab) and OKT3γ1 Ala-Ala (teplizumab). Overall, when dosing was adequate, the results demonstrated that CD3 antibodies preserved β-cell function very efficiently, maintaining significantly high levels of endogenous insulin secretion in treated patients for up to 24 months after treatment. These data provided the first proof of concept for a long-term therapeutic effect in T1D following a short course administration of a therapeutic agent. Our aim is to review these data and to discuss them in the context of the pitfalls linked to pharmaceutical development, especially in the context of pediatric patients, as in autoimmune diabetes.

Fulltext: HTML , PDF (143KB)


This article has been cited by other articles:

Invasive fungal infections in paediatric patients treated with macromolecular immunomodulators other than tumour necrosis alpha inhibitors

Kyriakidis I, Tragiannidis A, Zündorf I, Groll AH

Mycoses 2017. In press

Entire CD3ε, δ, and γ humanized mouse to evaluate human CD3-mediated therapeutics

Ueda O, Wada NA, Kinoshita Y, Hino H, Kakefuda M, Ito T, Fujii E, Noguchi M, Sato K, Morita M, Tateishi H, Matsumoto K, Goto C, Kawase Y, Kato A, Hattori K, Nezu J, Ishiguro T, Jishage KI

Sci Rep 2017. 7:45839

Mucosal administration of CD3-specific monoclonal antibody inhibits diabetes in NOD mice and in a preclinical mouse model transgenic for the CD3 epsilon chain

Kuhn C, Rezende RM, da Cunha AP, Valette F, Quintana FJ, Chatenoud L, Weiner HL

J Autoimmun 2016. In press

The homing and inhibiting effects of hNSCs-BMP4 on human glioma stem cells

Liu S, Yin F, Zhao M, Zhou C, Ren J, Huang Q, Zhao Z, Mitra R, Fan W, Fan M

Oncotarget 2016. 7(14):17920-17931

Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside

Kuhn C, Weiner HL

Immunotherapy 2016. 8(8):889-906

Inducing and Administering Tregs to Treat Human Disease

Perdigoto AL, Chatenoud L, Bluestone JA, Herold KC

Front Immunol 2016. 6:654

Oral immune therapy: targeting the systemic immune system via the gut immune system for the treatment of inflammatory bowel disease

Ilan Y

Clin Transl Immunology 2016. 5(1):e60

Lung transplantation: chronic allograft dysfunction and establishing immune tolerance

Gracon AS, Wilkes DS

Hum Immunol 2014. 75(8):887-894

Type 1 diabetes therapy beyond T cell targeting: monocytes, B cells, and innate lymphocytes

Wong FS, Wen L

Rev Diabet Stud 2012. 9(4):289-304